PER Postgame: Maximizing Durability Across Retinal Disease — What 3 Years of Evidence Means for Your Practice

Activity Overview

Neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) are significant drivers of vision loss— and they put substantial burdens on patients, including the need for regular anti-VEGF injections to treat them. In this program, an expert will provide insights into key questions regarding the use of next-generation anti-VEGF agents that can reduce patients’ treatment burden.

Target Audience

This activity is directed towards retina specialists, comprehensive ophthalmologists, and other eye care professionals involved in the treatment of neovascular retinal disease including nAMD, DME, and RVO.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Interpret extension data from clinical trials to evaluate the long-term durability profile of next-generation anti-VEGF agents in nAMD, DME, and DR, including the proportion of patients achieving extended dosing intervals beyond every 12 weeks.
• Apply clinical trial data to develop evidence-based extended-interval dosing strategies for patients with macular edema following RVO.
• Formulate individualized treatment selection and switching decisions using current comparative evidence, real-world outcomes, and label-supported dosing flexibility for patients across the spectrum of neovascular retinal disease.

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.

This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.

The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.

This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.